Tetracosapentaenoic Acid Treatment for AMD, Diabetic Retinopathy and Glaucoma

Brief Description

An innovative approach using tetracosapentaenoic acid to treat age-related eye disorders by replenishing critical lipids in the retina.

Full Description

Researchers at UC Irvine have developed a method using tetracosapentaenoic acid to address age-related eye disorders such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. This approach focuses on increasing the production of very long chain polyunsaturated acids (VLC-PUFAs) and docosahexaenoic acid (DHA), essential lipids that diminish with age, thereby improving retinal function and vision health.

Suggested uses

• Treatment for various age-related eye disorders 
• Supplementation for individuals with decreased VLC-PUFA and DHA production due to aging 
• Potential application in preventive treatments for populations at risk of developing age-related eye conditions

Advantages

• Directly increases VLC-PUFA and DHA production, essential for retina health.
• More effective delivery method compared to oral medications.
• Provides a direct, specific, and reproducible method to deliver the active compound to the retina.
• Addresses the underlying cause of lipid decrease in aging retinas.

Patent Status

Patent Pending